Calithera Biosciences (NASDAQ:CALA) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Friday.
Shares of CALA stock traded up $0.01 on Friday, hitting $6.43. The stock had a trading volume of 400,800 shares, compared to its average volume of 164,533. The company has a market capitalization of $254.78 million, a P/E ratio of -4.32 and a beta of 2.28. Calithera Biosciences has a one year low of $3.55 and a one year high of $7.65.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.03). Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 39.19%. On average, analysts predict that Calithera Biosciences will post -1.82 EPS for the current year.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.